Blood-Based Biomarker Market Applications in Cancer Neurological Disorders and Drug Discovery

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Blood-Based Biomarker Market - (By Type (Screening Biomarker, Diagnosis Biomarker, Others), By Disease (Cancer, Neurological Disorders, Others), By Application (Diagnostics, Drug Discovery, Personalized Medicine)), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."

Global Blood-Based Biomarker Market Size is valued at USD 7.9 Bn in 2024 and is predicted to reach USD 15.9 Bn by the year 2034 at a 7.4% CAGR during the forecast period for 2025-2034.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2244

Biomarkers are defined as measurable biological molecules, genes, or characteristics present in living organisms that provide critical insights into normal and pathological biological processes, disease progression, and therapeutic responses. These indicators are typically detected and quantified in biological fluids or tissues, such as blood, urine, saliva, and biopsied specimens.

The global biomarkers market is experiencing robust growth, driven primarily by the rising prevalence of chronic diseases, including cancer, cardiovascular disorders, neurological conditions, and infectious diseases. Concurrently, advancements in high-throughput omics technologies-particularly proteomics and metabolomics-are accelerating biomarker discovery and analysis, enabling broader applications in both clinical and research settings.

Technological innovations have enhanced the identification of novel biomarkers and the development of biomarker-based diagnostics, including biomarker signatures, which are improving prognostic accuracy, particularly in neurological disorders. Additionally, the increasing incidence of infectious diseases, the emergence of rare genetic disorders, and the growth of the aging population are expected to further fuel market expansion.

Biomarkers also hold critical value in pharmaceutical research, where they are utilized for drug development, safety assessment, and precision diagnostics. Their role in detecting disease presence, evaluating progression risk, and informing personalized treatment strategies underscores their significance across clinical, translational, and pharmaceutical applications.

List of Prominent Players in the Blood-Based Biomarker Market:
• Diadem srl
• Proteomedix
• Cleveland Diagnostics
• F. Hoffmann-La Roche Ltd.
• GENFIT
• Nutech Cancer Biomarkers India Pvt Ltd.
• SysmOex Corporation,
• Minomic,
• Creative Diagnostics,
• Eisai Co., Ltd.,
• C2N Diagnostics
• Others

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04

Market Dynamics
Drivers:
The global biomarker market is witnessing robust growth, driven by continuous scientific advancements, increasing recognition of biomarker potential, the promise of improved therapeutic outcomes, and supportive regulatory frameworks. Biomarkers are reshaping the healthcare landscape by enabling accurate diagnosis, facilitating early detection, guiding timely therapeutic interventions, and supporting ongoing monitoring of disease progression. As a result, pharmaceutical companies, biotechnology firms, academic research institutions, and government organizations are investing significantly in biomarker development to optimize patient care and reduce overall healthcare expenditures. These concerted efforts are expected to sustain market expansion over the forecast period.

Challenges:
Despite positive growth prospects, the biomarker market faces several challenges, particularly in establishing the cost-effectiveness and clinical utility of biomarker-based assays. Demonstrating diagnostic accuracy, improved clinical outcomes, and measurable healthcare cost savings is critical to broader adoption. However, the validation of novel biomarkers is resource-intensive, requiring substantial time and financial investment. In addition, limited or delayed reimbursement for biomarker testing can hinder market growth, particularly for newly introduced or advanced diagnostic solutions.

Regional Trends:
North America is projected to maintain a dominant share of the global biomarker market, supported by strong revenue growth and a high compound annual growth rate (CAGR) over the forecast period. The region benefits from a mature biotechnology and pharmaceutical sector, substantial investment in research and development, a well-established healthcare infrastructure, and favorable regulatory frameworks, all of which facilitate widespread adoption of biomarker-based diagnostics and therapeutics. Globally, the market for blood-based biomarkers is also expected to expand steadily, driven by the increasing prevalence of cancer and neurological disorders.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2244

Recent Developments:
• In May 2023, Proteomedix made an official declaration regarding the agreement that has been reached, whereby Labcorp will take sole responsibility for developing and commercialising the Proclarix® Prostate Specific Antigen (PSA) test within the United States. Proclarix was developed to assist in identifying the risk of prostate cancer in men without a cancer suspicion who had an elevated total prostate-specific antigen (PSA) and a digital rectal examination demonstrating an enlarged prostate volume. The procedure utilized the identical blood sample as the PSA test. When applicable, the test provided a non-invasive substitute for a prostate biopsy, a procedure known for its substantial adverse effects.

Segmentation of Blood-Based Biomarker Market-
By Type-
• Screening Biomarker
• Diagnosis Biomarker
• Others
By Disease-
• Cancer
• Neurological Disorders
• Others
By Application-
• Diagnostics
• Drug Discovery
• Personalized Medicine
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/blood-based-biomarker-market/2244

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: https://www.insightaceanalytic.com/
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.